Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Geriatric Depression
- Late Life Depression
- Major Depressive Disorder
- Treatment Resistant Depression
- Treatment-Refractory Depression
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 60 years and 125 years
- Gender
- Both males and females
Description
Older adult participants with treatment-resistant depression will be randomly assigned to a Step 1 medication strategy. Adding aripiprazole to current antidepressant medication Adding bupropion to current antidepressant medication Replacing current antidepressant medication with bupropion If depress...
Older adult participants with treatment-resistant depression will be randomly assigned to a Step 1 medication strategy. Adding aripiprazole to current antidepressant medication Adding bupropion to current antidepressant medication Replacing current antidepressant medication with bupropion If depression is not relieved at the end of 10 weeks, or if participants do not qualify for Step 1, participants will be randomly assigned to a Step 2 medication strategy: Adding lithium to current antidepressant medication Replacing current antidepressant medication with nortriptyline All medication strategies will be offered in collaboration with participants' own physicians with the the research team providing support and guidance. After treatment in Step 1 and/or Step 2, participants will enter the Continuation Phase to assess long term follow-up outcomes for 12 months. Participants in this clinical trial will also be asked to participate in an additional study to gather imaging and biomarker data.
Tracking Information
- NCT #
- NCT02960763
- Collaborators
- Patient-Centered Outcomes Research Institute
- National Institute of Mental Health (NIMH)
- Investigators
- Principal Investigator: Eric Lenze, MD Washington University School of Medicine
Get Well Soon